Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
<p>Abstract</p> <p>Background</p> <p>Gastrointestinal stromal tumors (GISTs), the most common type of mesenchymal tumors of the gastrointestinal (GI) tract, demonstrate positive kit staining. We report our surgical experience with 100 small intestine GIST patients and i...
Main Authors: | Jan Yi-Yin, Hwang Tsann-Long, Chao Tzu-Chieh, Wu Pei-Yu, Yeh Chun-Nan, Lee Li-Yu, Wu Ting-Jung, Chen Miin-Fu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2006-10-01
|
Series: | BMC Gastroenterology |
Online Access: | http://www.biomedcentral.com/1471-230X/6/29 |
Similar Items
-
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
by: Sumin Tang, et al.
Published: (2017-04-01) -
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
by: Omar S Din, et al.
Published: (2008-03-01) -
Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease
by: Rebecca M. Platoff, et al.
Published: (2017-01-01) -
A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome
by: Jiang Ming, et al.
Published: (2010-05-01) -
ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor.
by: Lori Rink, et al.
Published: (2013-01-01)